计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)
In Vitro
Pavurutamab (0-10000 pM; 48 h) induces CD69 + , CD25 + T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models. Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs. Dosage: 0.02, 0.2 and 2 mg/kg. Administration: Intravenous injection; single dose on days 3, 8, 13. Result: Reduced tumor volume. Animal Model: NOD/SCID mice orthotopically transplanted with L-363 MM cells. Dosage: 0.005, 0.05 and 0.5 mg/kg. Administration: Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days. Result: Reduced tumor volume and increased survival.
IC50& Target:B cell maturation antigens, BCMA